Conavi Begins Launch of Octiv Hybrid Imaging System for PCI Guidance

November 5, 2026—Conavi Medical Corp. announced the completion of the first United States placement and clinical cases with the company’s Octiv imaging system, powered by the company’s Novasight technology.

According to the company, the Octiv system combines optical coherence tomography (OCT) and intravascular ultrasound (IVUS) in a single imaging catheter to provide simultaneous, coregistered views of coronary arteries to support assessment of coronary artery disease and guide percutaneous coronary intervention.

The procedures were performed by interventional cardiologist Megha Prasad, MD, at NewYork-Presbyterian/Columbia University Irving Medical Center in New York, New York. This is the first site in the targeted rollout of Octiv that is being conducted by the company.

In April 2026, Conavi announced that the next-generation hybrid imaging system received FDA 510(k) clearance.

The company stated that the system’s commercial name, Octiv, refers to its combination of OCT and IVUS and is inspired by the musical term “octave”, reflecting the two complementary imaging modalities working in harmony.

“Having IVUS and OCT available in a single catheter gives us complementary information about the vessel during a coronary intervention,” commented Dr. Prasad in Conavi’s press release. “In our first week with the Octiv hybrid IVUS-OCT system, the device helped us identify a range of issues, from in-stent restenosis to dissections and plaque ruptures, findings that helped inform our treatment plans.”

Dr. Prasad continued, “In ostial and multivessel cases, we were able to switch between hybrid and IVUS-only runs, which gave us the full fOctiv picture while conserving contrast. Paired with physiology, it also helped us assess vessels in patients with microvascular disease.” Dr. Prasad also delivered a podium presentation at TCT 2026 featuring hybrid IVUS–OCT imaging, preclinical research, and physician education sessions, noted the company.